Intrommune Therapeutics Completes Last Patient Last Visit in Phase 1 OMEGA Study

Intrommune Therapeutics, Inc., a clinical stage biotechnology company, has successfully completed the final visit of the last patient in the Phase 1 OMEGA Clinical Study for individuals with peanut allergy. This 48-week trial is specifically designed for adults with peanut allergies and aims to gather long-term safety data while determining the appropriate starting dose for INT301, an innovative..

  • format_list_bulleted BS
  • · 2023. 7. 26.
  • textsms

IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

IntelGenx Corp. has recently announced a groundbreaking research collaboration with Karolinska University Hospital. The focus of this collaboration is to explore the potential of using Montelukast VersaFilm® as a treatment for Parkinson's Disease. Led by the esteemed Professor Per Svenningsson, an expert in clinical neuroscience, this study will delve into the efficacy of IntelGenx's innovative ..

  • format_list_bulleted BS
  • · 2023. 7. 26.
  • textsms

Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune

Grifols, a global leader in the production of plasma-derived medicines, has announced positive results from a Phase 4 study investigating the use of XEMBIFY®, its subcutaneous immunoglobulin product, administered every two weeks. The study successfully met its primary objective by demonstrating comparable levels of total immunoglobulins when compared to weekly administration in patients with pri..

  • format_list_bulleted BS
  • · 2023. 7. 21.
  • textsms

Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics has announced the planned pivotal Phase 3 study design for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in the treatment of Microcystic Lymphatic Malformations. The announcement was made by the clinical-stage biopharmaceutical company, which aims to address the lack of FDA-approved therapies for this rare genetic disease. The Phase 2 results demonstrated signifi..

  • format_list_bulleted BS
  • · 2023. 7. 21.
  • textsms

"ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023"

The Phase 3 data of donanemab, a potential treatment for Alzheimer's disease, has been announced by the Alzheimer's Association. The data, presented at the Alzheimer's Association International Conference® (AAIC®) 2023 by Eli Lilly and Company, showcases promising advancements in Alzheimer's research and treatment. &nbsp In the TRAILBLAZER-ALZ 2 clinical trial, donanemab demonstrated its ability..

  • format_list_bulleted BS
  • · 2023. 7. 18.
  • textsms

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Successfully Enrolls Targeted Number of Patients in Phase 3 Study of Prolastin®-C for Emphysema Due to Alpha-1-Antitrypsin Deficiency Grifols, a global leader in plasma-derived medicines, has achieved its enrollment goal of 339 patients for the SPARTA clinical trial. This groundbreaking study aims to assess the effectiveness and safety of two different weekly doses of Grifols' Prolastin®..

  • format_list_bulleted BS
  • · 2023. 7. 14.
  • textsms

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics, a biotechnology company specializing in targeted and immuno-oncology therapeutics, has announced the initiation of Part B of the DeFianCe study for DKN-01 in colorectal cancer patients. This study aims to assess the effectiveness of Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, when combined with standard care bevacizumab and chemotherapy as a second-line treatment for advan..

  • format_list_bulleted BS
  • · 2023. 7. 13.
  • textsms

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study for SerpinPC in Hemophilia B Treatment

16">The study aims to determine the effectiveness of SerpinPC in reducing bleeds in individuals with hemophilia B. Hemophilia B is a rare genetic disorder that affects the blood's ability to clot properly, leading to prolonged bleeding and increased risk of complications. Current treatment options for hemophilia B include regular infusions of clotting factors, but these can be costly and time-co..

  • format_list_bulleted BS
  • · 2023. 7. 11.
  • textsms

Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)

Biodexa Ltd, a clinical stage biopharmaceutical company, has successfully completed the enrollment and treatment phase of the Phase 1 study for MTX110. This study focused on treating children with newly diagnosed Diffuse Midline Gliomas (DMGs), a type of primary brain tumor that primarily affects children and has a poor prognosis. The study took place at Columbia University Irving Medical Centre..

  • format_list_bulleted BS
  • · 2023. 7. 11.
  • textsms

Less Than Half of New Drug Approvals Add Therapeutic Value Over Existing Treatments: Study

Less than half of the new drug approvals are actually providing therapeutic value to patients, according to a recent study published in The BMJ. Despite the increasing number of drugs being approved in both the U.S. and Europe, it seems that many of them are not significantly improving patient outcomes. The study focused on 124 first indications that were approved by the FDA and European Medicin..

  • format_list_bulleted BS
  • · 2023. 7. 10.
  • textsms